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Glial cell-line-derived neurotrophic factor (GDNF) is
a potent neurotrophic factor that has reached clinical
trials for Parkinson’s disease. GDNF binds to its
coreceptor GFRa1 and signals through the trans-
membrane receptor tyrosine kinase RET, or RET in-
dependently through NCAMor syndecan-3.Whereas
the GDNF signaling cascades are well described,
cellular turnover and trafficking of GDNF and its
receptors remain poorly characterized. Here, we
find that SorLA acts as sorting receptor for the
GDNF/GFRa1 complex, directing it from the cell
surface to endosomes. Through this mechanism,
GDNF is targeted to lysosomes and degraded while
GFRa1 recycles, creating an efficient GDNF clear-
ance pathway. The SorLA/GFRa1 complex further
targets RET for endocytosis but not for degrada-
tion, affectingGDNF-induced neurotrophic activities.
SorLA-deficient mice display elevated GDNF levels,
altered dopaminergic function, marked hyperac-
tivity, and reduced anxiety, all of which are pheno-
types related to abnormal GDNF activity. Taken
together, these findings establish SorLA as a critical
regulator of GDNF activity in the CNS.INTRODUCTION
Neurotrophic factors are key molecules in sculpting the devel-
oping nervous system as well as regulating adult neuronal main-
tenance and plasticity. Glial cell line-derived neurotrophic factor
(GDNF) is essential for the development of several neuronal pop-
ulations (Airaksinen and Saarma, 2002), and a critical survival
factor for a number of neuronal subtypes, most notably midbrain
dopaminergic (DA) neurons (Lin et al., 1993). More specifically,
GDNF protects and repairs nigral DA neurons in neurotoxin-186 Cell Reports 3, 186–199, January 31, 2013 ª2013 The Authorslesioned animal models of Parkinson’s disease (Kirik et al.,
2004), and phase I clinical trials with parkinsonian patients,
GDNF gave highly promising results that were unfortunately
hampered by conflicting outcome from phase II studies (Gill
et al., 2003; Lang et al., 2006).
GDNF is a homodimeric neurotrophic factor belonging to the
GDNF family ligands (GFLs) together with neurturin, persephin,
and artemin (Airaksinen and Saarma, 2002). GDNF signaling is
conventionally mediated via two receptors. First, the GDNF
dimer binds GDNF family receptor a1 (GFRa1), which is linked
to the plasma membrane through a glycosylphosphatidylinositol
anchor. The resulting tetrameric (2:2) complex interacts with
Rearranged During Transfection (RET) receptor tyrosine kinase
and activates Erk, Akt, Src, and PLCg pathways (Airaksinen
and Saarma, 2002). Although RET is the established GDNF
signaling receptor, many cells responding toGDNF and express-
ing GFRa1 do not express RET (Trupp et al., 1997; Yu et al.,
1998). To date, two alternative receptors have been discovered:
neural cell adhesion molecule N-CAM and syndecan-3 (Bespa-
lov et al., 2011; Paratcha et al., 2003). In both cases, the
ligand-receptor interaction leads to the activation of Src family
kinases, modulating cell migration, neurite outgrowth, and syn-
apse formation (Bespalov et al., 2011; Iba´n˜ez, 2010).
Despite the progress in characterizing GDNF receptors and
their signaling pathways, still very little is known about their traf-
ficking and how GDNF activity is regulated. Due to alternative
splicing, GDNF is synthesized in two precursor forms (a)- and
(b)proGDNF that are sorted differentially through the secretory
pathway prior to propeptide cleavage by a proprotein con-
vertase (Lonka-Nevalaita et al., 2010), a process proposed to
involve the sorting receptor SorLA (Geng et al., 2011; Wester-
gaard et al., 2004). SorLA is one of five members of the sorti-
lin-related receptor family (sortilins), unified by the vacuolar
protein sorting protein 10p (Vps10p) domain (Jacobsen et al.,
1996; Willnow et al., 2008). The cytoplasmic tail of SorLA
contains several consensus binding sites for adaptor proteins
that mediate internalization from the cell surface, Golgi-endo-
some transport, and retrograde sorting to the TGN (Nielsen
et al., 2007). In the present study, we find that SorLA conveys
internalization of GFRa1 alone and in complex with GDNF and
mediates their sorting to endosomal compartments. GFRa1
bypasses lysosomal degradation, whereas GDNF does not.
The SorLA/GFRa1 complex further mediates subcellular sorting
of RET, influencing GDNF-induced neurotrophic activity includ-
ing the survival of primary DA neurons. SorLA-deficient mice
have increased GDNF levels in the striatum andmidbrain and ex-
hibit a behavioral phenotype characterized by reduced anxiety,
hyperactivity, and insensitivity to amphetamine, symptoms remi-
niscent of attention deficit hyperactivity disorder (ADHD) in
humans.
RESULTS
SorLA Selectively Binds GDNF
GDNFbound to the extracellular domain of SorLA in a concentra-
tion-dependent manner as assessed using Biacore (Figure 1A).
The interaction was of high affinity with a Kd of 3 nM, and selec-
tive as no other GFL showed binding to SorLA (Figure 1B). GDNF
is unique among the GFLs by containing an extended N terminus
of 38 amino acids (Baloh et al., 2000). As this region might
contribute to SorLA binding, we generated a glutathione S-trans-
ferase (GST) fusion peptide encompassing theGDNF propeptide
followed by the N-terminal extension (GDNF aa 20–115). This
peptide bound SorLA with a Kd of 76 nM, whereas neither
GST-GDNF propeptide (GDNF aa 20–77) nor GST-neurturin pro-
peptide displayed any binding, clearly indicating that the GDNF
N-terminal region is involved in binding of SorLA (Figure 1C
and data not shown). The 25-fold difference in the affinity of
GDNF to SorLA compared to the N-terminal peptide could be
due to additional degrees of freedom of the peptide fragment
when not covalently associated with the folded structure of
GDNF. However, at present, the involvement of other GDNF
regions in SorLA binding cannot be excluded either. SorLA is
a large mosaic receptor containing several potential ligand
binding domains, one of which is the Vps10p domain (Figure 1D).
Prior to its removal in late Golgi compartments, the SorLA pro-
peptide inhibits access to this domain (Jacobsen et al., 2001).
We found that excess SorLA propeptide prevented the binding
of GDNF to SorLA (Figure S1A). In analogy, 200-fold molar
excess of the small neuropeptide neurotensin, predicted to
bind inside the tunnel-like cavity of the SorLA Vps10p domain
(Quistgaard et al., 2009), also abolished GDNF binding to SorLA
in Biacore experiments (Figure S1B). The SorLA-GDNF interac-
tion was further confirmed in HEK293 cells transfected with an
endocytosis-deficient SorLA mutant where the binding of 125I-
GDNF (100 pM) was displaced by increasing concentrations of
unlabelled GDNF (Figure S1C). The combined data demonstrate
that the SorLA Vps10p domain specifically and selectively binds
to the N-terminal region of GDNF.
SorLA and GFRa1 Direct GDNF to Lysosomes
SorLA rapidly traffics from the cell surface to endosomes (Niel-
sen et al., 2007). Thus, to study SorLA-mediated GDNF endocy-
tosis and how this was affected by the presence of the GDNF
signaling receptors, we used HEK293 cells transfected with
combinations of SorLA, GFRa1, and RET. Cells were incubated
with GDNF (3 nM) for 2 hr on ice to allow cell surface bindingCbefore changing to 37C medium without GDNF to commence
internalization for 30min. Analysis using confocal microscopy re-
vealed GDNF in vesicular structures of SorLA cells, whereas faint
spots of GDNF lined the surface of cells transfected with RET or
empty vector (Figure 1E). In contrast, GFRa1 or GFRa1/RET-
expressing cells showed intense GDNF staining lining the
plasmamembrane, but no endocytosiswas apparent (Figure 1E).
GDNF endocytosis by RET/SorLA cells was comparable to
SorLA alone (Figure 1E). Strikingly, coexpression of SorLA and
GFRa1 resulted in a dramatic increase in GDNF endocytosis
independent of RET (Figures 1E and S1D). In fact, SorLA and
GFRa1 together resulted in detectable internalization at a 100-
fold lower GDNF concentration compared to SorLA alone
(Figures S1E and S1F), demonstrating a cooperative effect.
Furthermore, GDNF surface staining was reduced by 75%
during 45 min in SorLA/GFRa1 cells compared to only 30%
in GFRa1 cells (Figures S2A and S2B).
Interestingly, SorLA cells metabolized GDNF from the culture
medium to a much greater extent than mock-transfected cells
(Figure S2C), and 125I-GDNF bound to the surface of cells
expressing SorLA, decreased from 3,214 ± 450 to 1,046 ± 72
cpm during 60 min, and was accompanied by an equivalent
accumulation of nonprecipitable radioactivity released into the
culture medium, possibly derived from degraded GDNF (Fig-
ure S2D). Importantly, GDNF did not remain associated with
SorLA and GFRa1 but colocalized with the endosomal marker
EEA1 (Figure 1F), and the intensity of the GDNF staining
decreased over time (from 30 to 60 min) (Figures 1Fand 1G).
Lysosome inhibition by leupeptin and pepstatin (leu/pep) clearly
augmented GDNF immunoreactivity in structures of SorLA/
GFRa1 cells also positive for the lysosomal marker Lamp-1 (Fig-
ure 1G). In contrast, no change in GDNF staining upon leu/pep
treatment was evident in GFRa1 cells, where abundant GDNF
was associated with the plasma membrane (Figure 1H). Taken
together, the data show that SorLA alone and in cooperation
with GFRa1 of the GFRa1-RET complex binds extracellular
GDNF and targets it for lysosomal degradation.
GFRa1 and SorLA Forms GDNF Sorting Complex
To study how GFRa1 delivers GDNF to SorLA, we probed for
a receptor-receptor complex by coimmunoprecipitation (co-
IP). Indeed, SorLA and GFRa1 co-IPed both in the presence
and absence of GDNF (Figure 2A), whereas we were unable
to co-IP SorLA and RET (data not shown). The SorLA/GFRa1
interaction was direct as assessed using Biacore (Kd = 6 nM)
(Figures 2B and S3A), whereas we observed no binding between
the SorLA and RET (Figure 2B). GFRa1 binding was inhibited by
excess SorLA propeptide (Figure S3B), but, unlike for GDNF,
neurotensin did not affect the SorLA-GFRa1 interaction (Fig-
ure S3C). We speculated whether SorLA-GFRa1-GDNF might
interact simultaneously and tested this in a Biacore experiment
where immobilized SorLA was first saturated with GDNF and
subsequently tested for its ability to bind GFRa1. No reduction
in the affinity for GFRa1 was observed for the SorLA-GDNF com-
plex compared to SorLA alone (Figure S3D). In fact, picomolar
GDNF concentrations increased SorLA/GFRa1 co-IP, indicating
the potential formation of a ternary complex (Figure S3E). Finally,
by crosslinking followed by sequential co-IP of GDNF andell Reports 3, 186–199, January 31, 2013 ª2013 The Authors 187
Figure 1. SorLA and GFRa1 Direct GDNF to Lysosomes
(A) GDNF binds SorLA in a concentration-dependent manner as shown using Biacore. Kd = 3 nM.
(B) Binding to SorLA is selective for GDNF and not observed for artemin, neurturin, or persephin (20 nM).
(C) Binding of proGDNF N-terminal fragments containing the proregion and first 38 amino acids (aa 20–115) from the mature GDNF fused to GST (200 nM) to
immobilized SorLA ECD. The binding site in GDNF is encompassed within the N-terminal 38 aa of mature GDNF. Numbering starts from the human GDNF signal
peptide. The aa 20–77 construct contains only the proregion of GDNF.
(D) The domain structure of SorLA and the related receptor sortilin is depicted. Vps10p, vacuolar protein sorting 10 protein; EGF, epidermal growth factor class
B-like domain; LA, LDL class A repeats; Fbn III, fibronectin type III repeats.
(E) Mock-transfected HEK293 cells or HEK293 cells transfected with combinations of SorLA, GFRa1, and RET as indicated were incubated with GDNF (3 nM) at
0C for 2 hr on ice to allow surface binding but not internalization. Cells were subsequently changed to 37C culture medium for 30 min. GDNF (green) and SorLA
(red) are visualized by IF. All images were obtained using the same laser power and microscope settings. Nuclei are stained using Hoechst. Scale bar, 10 mm.
n = 10 independent experiments with over 300 cells evaluated for each condition.
(legend continued on next page)
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Figure 2. SorLA and GFRa1 Form a GDNF
Sorting Complex
(A)SorLA interactsdirectlywithGFRa1asshownby
co-IP in transfected HEK293 cells ± GDNF (5 nM).
(B) Specific interaction of GFRa1 but not RET
extracellular domain (200 nM of either) with SorLA
as shown using Biacore.
(C) Surface-labeled GFRa1 (green) is endocytosed
in HEK293 cells coexpressing SorLA ± GDNF.
GFRa1 expressed alone is not endocytosed
during the course of the experiment. Scale bar,
10 mm. n = 10 independent experiments with over
300 cells evaluated for each condition.
(D) Quantification of the decrease in GFRa1
surface IF over time in GFRa1- or GFRa1/SorLA-
expressing HEK293 cells ± GDNF (*p = 0.005,
**p = 3E-5). Error bars indicate SEM.
(E) Turnover of GFRa1 in transfected HEK293 ±
SorLA was assessed by metabolic labeling fol-
lowed by pulse-chase analysis and subsequent IP.
(F)SorLAandGFRa1colocalizewith the trans-Golgi
marker TGN46 in HEK293/SorLA/GFRa1 cells.
(G) Immunoelectron microscopy showing colocal-
ization of SorLA and GFRa1 in endosomes (E) and
multivesicular bodies (MVB) visualized by staining
of HEK293/SorLA/GFRa1 cells with first mouse
anti-SorLAandgoat anti-GFRa1, andsubsequently
with gold-particle-coupled donkey anti-mouse
(10 nm particle diameter) and donkey anti-goat
(6 nm particle diameter) secondary antibodies.
MVBsaremagnified in right imagesandwhitearrow
heads indicate 6 nm particles close to 10 nm par-
ticles, representing colocalized SorLA and GFRa1.
See also Figures S3 and S4.GFRa1 as described in Figure S3F, SorLA was pulled down
specifically as part of a ternary SorLA/GFRa1/GDNF complex,
confirming its existence.(F) GDNF (green) (3 nM) internalized by HEK293/SorLA/GFRa1 cells for the indicated time periods displays
(red) but instead colocalize with the endosomal marker EEA1 (red). All images were acquired at the same lase
decrease in GDNF vesicular staining over time.
(G and H) Inhibition of lysosomal proteinases using leupeptin and pepstatin (leu/pep) prevents degradation o
SorLA/GFRa1 as visualized by the increase of GDNF IF (green) colocalizing with Lamp-1 (red). In contrast, i
membrane was observed in HEK293/GFRa1 cells independent of treatment. Experiments in (F) and (G) we
evaluated for each condition. Representative images are shown. Scale bar, 10 mm. All images were obtained w
See also Figures S1 and S2.
Cell Reports 3, 186–199SorLA Sorts GFRa1 from the Cell
Surface to the TGN
To monitor SorLA-mediated sorting of
GFRa1, we labeled surface receptor with
antibodies. In the presence of SorLA, the
majority of GFRa1 accumulated in para-
nuclear compartments within 45 min,
whereas no endocytosis was observed
for GFRa1 alone (Figures 2C and 2D). To
determine if SorLA destines GFRa1 for
lysosomal degradation, we studied its
turnover by metabolic labeling of cells ex-
pressing GFRa1 alone or coexpressing
SorLA. Surprisingly, SorLA appeared toprolong GFRa1 half-life, ruling out lysosomal sorting (Figures
2E, S3G, and S3H). GFRa1 alone localized mainly to the plasma
membrane, but coexpression with SorLA shifted a substantialonly modest colocalization with SorLA and GFRa1
r power and microscope settings and illustrate the
f GDNF (3 nM, 60 min) in HEK293 cells expressing
ntense GDNF staining associated with the plasma
re performed six times and at least 200 cells were
ith the same laser power andmicroscope settings.
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Figure 3. The SorLA/GFRa1 Complex Mediates RET Endocytosis
(A) Co-IP of RET together with GFRa1 ± SorLA from transfected HEK293 cells (left part of figure). Co-IP of SorLA together with GFRa1 ± RET (right part of figure).
n = 4 independent experiments.
(B and C) HEK293 cells transfected with combinations of RET, SorLA, GFRa1, or empty vector were incubated on ice for 2 hr in medium containing antibodies
against the RET extracellular domain (0.1 mg/ml) and subsequently 0 or 30min at 37C in normal culturemedium. Scale bar, 10 mm. n = 4 independent experiments
with over 100 cells evaluated for each condition.
(D) RET (green) is internalized into EEA1- (red) positive endosomes by the SorLA/GFRa1 complex ± GDNF (3 nM). Scale bar, 10 mm.
(E) To separate the subcellular structures that contain endogenous RET, we performed a two-step sucrose gradient centrifugation of a postnuclear supernatant
preparation of SY5Y or SY5Y/SorLA cells. We first fractioned cells by velocity gradient centrifugation and assessed the presence of SorLA and RET in collected
fractions by western blotting as shown in Figure S5B. Fractions 7–9, enriched in both SorLA and RET, were pooled and further fractioned by an equilibrium
gradient centrifugation, and collected fractions were analyzed again as indicated in the figure. n = 3 independent experiments.
(F) The effect of SorLA overexpression (SY5Y/SorLA) on turnover of endogenous RET in SY5Y neuroblastoma cells was assessed by metabolic labeling followed
by pulse-chase analysis and subsequent IP of RET. n = 4 independent experiments.
See also Figure S5.fraction of GFRa1 to vesicular structures (Figure S3I). SorLA and
GFRa1 partially colocalized with the TGN marker TGN46 (Fig-
ure 2F) and were also found together in endosomes and multive-
sicular bodies as shown by immune electron microscopy (Fig-
ure 2G). Although SorLA does not bind the additional GFLs, it is
tempting to speculate that it may sort neurturin coreceptor
(GFRa2), artemin coreceptor (GFRa3) and persephin coreceptor
(GFRa4) in a similarmanner toGFRa1. Indeed, SorLAwas specif-
ically pulled down by co-IP with the individual GFRas (Fig-
ure S4A). Furthermore, SorLA directed GFRa2 and -4 from the
cell surface into vesicles (Figures S4B–S4D), suggesting that it
may function as a general GFRa sorting receptor.190 Cell Reports 3, 186–199, January 31, 2013 ª2013 The AuthorsSorLA/GFRa1 Mediates RET Endocytosis
We next tested if SorLA affects RET/GFRa1 complex formation.
Intriguingly, SorLA did not inhibit pulldown of RET and GFRa1;
rather, it appeared to increase their interaction slightly (Fig-
ure 3A). Of note, the presence of SorLA mainly induced co-IP
of GFRa1 with the lower molecular weight form of RET, likely
representing immature intracellular receptor. Similarly, co-IP of
SorLA by GFRa1 was also somewhat increased by RET despite
the fact that we were unable to demonstrate an interaction
between SorLA and RET (Figure 3A and data not shown). This
was not altered by the presence of GDNF (3 nM) (data not
shown). To study if RET trafficking is affected by SorLA, we
Figure 4. SorLA Inhibits GDNF-Induced
Neurotrophic Activity
(A) SY5Y cells stimulated with GDNF (3 nM, 15min)
following 2 hr preincubation with the indicated
antibodies (10 mg/ml). Representative immuno-
blots of phosphorylated Erk (pErk) and phosphor-
ylated Akt (pAkt) and total levels of Erk and Akt
proteins. n = 3 independent experiments.
(B) The presence of goat anti-GDNF (10 mg/ml) in
the culture medium of serum-depleted SY5Y cells
for 3 days reduces their survival compared to the
presence of unspecific goat antibodies. *p = 0.04
(n = 4).
(C) Addition of exogenous GDNF (3 nM) and inhi-
bition of endogenous SorLA by its propeptide
(SorLApro, 1 mM) increases SY5Y cell survival
upon serum depletion. *p = 6E-5 compared to
the control. **p = 0.001 compared to the control.
***p = 1E-5 compared to SorLApro (n = 4).
(D) SorLA overexpression in SY5Y/SorLA cells
reduces survival upon serum depletion com-
pared to mock-transfected SY5Y cells. *p = 0.008
(n = 4).
(E) GDNF binding and uptake in SY5Y cells
and SY5Y/SorLA cells for 30 min at 37C fol-
lowing incubation in GDNF-containing medium
(3 nM) for 2 hr on ice. n = 3 independent ex-
periments with over 100 cells evaluated. Scale
bar, 10 mm.
(F) Inhibition of SorLA by its propeptide (SorLApro, 1 mM) increases proliferation of SY5Y cells (*p = 9E-4, **p = 4E-6, n = 4). GST alone (1 mM) was added to
SY5Y cells in the control experiment.
(G) Overexpression of SorLA inhibits GDNF-induced (3 nM) but not all trans-retinoic acid (RA)-induced (10 mM) neurite outgrowth in SY5Y cells. (*p = 0.03,
**p = 0.04, n = 5).
Error bars indicate SEM. See also Figure S5.labeled surface RET with antibodies and studied its internaliza-
tion. At 30 min the vast majority of labeled RET remained at
the surface of cells expressing RET alone, or RET together with
GFRa1 or SorLA (Figures 3B and 3C). However, in SorLA/
GFRa1/RET cells, RET was directed to EEA1-positive endo-
somes (Figures 3C and 3D), an observation that was indepen-
dent of GDNF (Figure 3D, left panel). We speculated if the
SorLA/GFRa1 complex sorts endogenous RET and tested this
in SY5Y cells, which express all three receptors endogenously,
and in SY5Y cells overexpressing SorLA (SY5Y/SorLA) (Fig-
ure S5A). To separate intracellular structures, we employed a
two step gradient centrifugation protocol (Nielsen et al., 2007)
and analyzed fractions by western blotting (Figures 3E and
S5B). This experiment revealed amarked shift in RET localization
in SY5Y/SorLA cells to fractions of higher density also enriched
in SorLA (Figure 3E), strongly indicating that RET undergoes
intracellular trafficking together with SorLA/GFRa1. Yet, such
sorting does not affect RET degradation as newly synthesized
receptor rapidly disappeared independent of SorLA overexpres-
sion (Figure 3F).
SorLA Inhibits GDNF-Induced Neurotrophic Activity
As SorLA targets all three components of the extracellular GDNF
signaling machinery, we tested its impact on the activation of
intracellular cascades. We treated SY5Y cells for 2 hr with SorLA
antibodies that block GDNF/GFRa1 endocytosis (Figure S5C)
and observed a marked increase in GDNF-induced Erk and AktCphosphorylation (3 nM, 15 min), suggesting an inhibitory role
of endogenous SorLA (Figure 4A). Serum-depleted SY5Y cells
depend on autocrine GDNF stimulation as anti-GDNF reduced
survival by 35% (Figure 4B). In contrast, survival was potenti-
ated by the addition of exogenous GDNF (Figure 4C). The SorLA
propeptide (SorLApro) can be used as a SorLA antagonist as
illustrated in Figures S5D and S5E. Accordingly, SorLApro
induced survival as efficiently as exogenously added GDNF,
and their combination was even more effective (Figure 4C). In
contrast, SorLA overexpression (SY5Y/SorLA) reduced survival
to a similar extent as anti-GDNF (Figure 4D). Notably, SY5Y/
SorLA cells also displayed markedly increased clearance of
surface bound GDNF (3 nM) during 30 min compared to mock-
transfected SY5Y cells (Figure 4E). GDNF-GFRa1-RET signaling
is further known to promote proliferation of SY5Y cells (Hirata
and Kiuchi, 2003), and in analogy the addition of SorLApro
markedly increased the number of cells/well after 24 hr (Fig-
ure 4F). Proliferation could not be potentiated further by addi-
tion of both GDNF and SorLA propeptide, suggesting that it
was already proceeding at its highest rate (data not shown).
Cell differentiation, e.g., neurite outgrowth is a third down-
stream effect of GDNF. Addition of GDNF to the culture medium
resulted in approximately 30% process-bearing SY5Y cells
(Figure 4G). However, SorLA overexpression blocked GDNF-
induced process outgrowth but did not significantly affect
outgrowth induced by retinoic acid (RA) that initiates a different
signaling cascade (Figure 4G). In summary, SorLA negativelyell Reports 3, 186–199, January 31, 2013 ª2013 The Authors 191
modulates downstream effects of GDNF signaling likely by con-
trolling both GDNF levels and the subcellular distribution of
GFRa1-RET.
SorLA Controls GFRa1 Localization and GDNF Uptake in
Neurons
Using western blotting, we found SorLA expressed in all CNS
tissues analyzed (Figure 5A), and immunohistochemistry of
mouse brain sections revealed the presence of SorLA in distinct
neuronal vesicular structures as exemplified in the cortex (Fig-
ure 5B) but also in GFAP-positive glia (Figures S6A and S6B).
GFRa1 is highly expressed in the developing cortex and hippo-
campus where it acts independent of RET (Bespalov et al.,
2011; Ledda et al., 2007; Pozas and Iba´n˜ez, 2005). In primary
hippocampal neurons, we detected high levels of endogenous
GFRa1 but not RET, and all neurons also expressed variable
levels of SorLA (Figure 5C and data not shown). Interestingly,
GFRa1 was markedly enriched in the initial segment of filaments
(Figure 5C). As SorLA-positive vesicles are abundant in the soma
and protrude gradually through the initial segment of filaments
(Figure 5C), we speculated if it might function here as sorting
hub for GFRa1 targeted for axons and dendrites. Indeed, such
GFRa1 enriched initial segments displayed much stronger sur-
face immunoreaction in neurons derived from SorLA knockout
(KO) mice (Figure 5D) albeit total GFRa1 levels were unaltered
in KO neurons compared to wild-type (WT) (Figure 5F). We there-
fore performed GFRa1 immunostainings of nonpermeabilized
neurons from both genotypes and quantified the relative inten-
sity of surface staining in the initial segments as illustrated in Fig-
ure 5D. Notably, lack of SorLA resulted in a marked increase in
surface GFRa1 in the soma and at the initial segment of filaments
(Figure 5E), showing that SorLA regulates GFRa1 subcellular
localization in neurons. We subsequently tested the ability of
hippocampal neurons to bind andmetabolize GDNF. Exogenous
GDNF (3 nM) avidly bound to the surface of neurons derived from
WT and KOmice upon incubation for 2 hr at 0C (Figures 5G and
5H). Following 30 min incubation in 37C culture medium, the
GDNF signal in the soma markedly decreased and was now
found in a few faint vesicles of WT neurons (Figure 5G). In con-
trast, GDNF remained associated with the surface of SorLA KO
neurons, suggesting that endogenous SorLA/GFRa1 complex
mediates its endocytosis (Figure 5H).
SorLA Regulates In Vivo GDNF Levels and GDNF-
Induced Survival of DA Neurons
The survival of midbrain dopaminergic (DA) neurons in culture
depends on exogenous GDNF in a RET-dependent manner, as
well as on a supporting layer of glial cells (Burke et al., 1998;
Lin et al., 1993). Interestingly, both glia and DA neurons were
found to express high levels of SorLA (Figures 6A–6C, S6A,
and S6B). Hence, SorLA might regulate DA survival by seques-
tering extracellular GDNF and altering the subcellular distribution
of its receptors. Accordingly, we found that when GFAP-positive
cortical glia were incubated with GDNF (3 nM), it accumulated
in vesicular structures within 15 min (Figures 6D and 6E). In
contrast, no GDNF internalization was observed in cells derived
from SorLA KOmice (Figure 6F). In addition, GFRa1 appeared to
be increased at the surface of DA neurons from SorLA KO192 Cell Reports 3, 186–199, January 31, 2013 ª2013 The Authorscompared to WT neurons where it was more pronounced in
vesicular structures (Figure 6G). We therefore cultured rat DA
neurons with anti-SorLA or unspecific immunoglobulin G (IgG)
in the culture medium. In the absence of GDNF, anti-SorLA did
not affect survival compared to the control (data not shown).
However, in the presence of GDNF (0.3 nM), SorLA inhibition
potentiated survival by nearly 50% (Figure 6H). Similarly, the
GDNF-induced survival of SorLA knockout DA neurons was
markedly increased compared to that of WT neurons (Figure 6I).
To determine if SorLA regulates the amount of GDNF available to
DA neurons in vivo, we first examined SorLA expression in the
adult DA system by immunohistochemistry. A clear SorLA stain-
ing was observed in vesicle-like structures in the soma of tyro-
sine hydroxylase (TH)-positive midbrain neurons, and also in
the surrounding cells (Figure 6J). In striatum, we observed abun-
dance of SorLA-expressing cells (Figure S6E), some of which
were also GFAP positive (Figure S6F). We next analyzed adult
striatal and midbrain homogenates for their content of GDNF
by ELISA and found it be highly elevated in KO mice compared
to WT (Figure 6K).
SorLA Deficiency Affects the DA System and
Anxiety-Related Behavior
We speculated that the absence of SorLA, and thus potentially
altered GDNF activity, might lead to abnormal functionality of
the DA system. The overall appearance of the midbrain DA sys-
tem of SorLA knockouts was normal compared to WT mice as
shown by TH staining (Figure S7A). Stereological counting
showed that the number ofmidbrain TH+ neurons in the substan-
tia nigra pars compacta (SNpc) and ventral tegmental area (VTA)
was unchanged in both young (5 weeks, n = 6 in each group) and
older (45 weeks, n = 3 in each group, data not shown) Sorl1/
mice compared to WT mice (Figures 7A and 7B). Also the length
density of TH+ nerve fiber protruding from theSNpcandVTA from
sections of 10-week-old mice was similar between genotypes
(Figures 7Cand7D). To assessDAconnectivity in thenigrostriatal
system, we performed unilateral intrastriatal injections of the
retrograde tracer cholera toxin b subunit (CTb). CTb-labeled
TH+ neurons in the SNpcwere then identified by double immuno-
fluorescence (IF) and counted. Remarkably, the number of CTb-
labeled DA neurons in knockouts was less than one-fourth of that
ofWTmice (Figures 7E, S7B, andS7C), showing that nigrostriatal
connectivity was severely perturbed. The reduction in nigros-
triatal connectivity was accompanied by approximately 50%
reduction in TH protein levels in striatum of SorLA knockouts as
assessed by western blotting (Figures 7F and 7G), and a slight
reduction in dopamine levels as measured by high-performance
liquid chromatography (HPLC) (Figures 7H and S7D–S7K).
The activity of midbrain DA neurons is instrumental in the
behavioral response to phychostimulants. We therefore tested
the role of SorLA in amphetamine-induced hyperlocomotion by
injecting WT and SorLA knockouts with either saline or amphet-
amine and monitoring their behavior in an open field. The loco-
motor activity of WT mice was increased approximately three
timesuponamphetamine (10mg/kg) administration and the aver-
age distance traveled during 40 min augmented from 58.28 ±
4.19m to 172.51 ± 19.88m (p = 2E-4). In contrast, saline-injected
KO mice were already hyperactive compared to WT controls
Figure 5. Neuronal Surface Level of GFRa1 Is Regulated by SorLA
(A) SorLA expression in the CNS of young (6 weeks) and old mice (96 weeks) shown in tissue homogenates analyzed by western blotting.
(B) Immunohistochemical staining for SorLA in cortical paraffin sections visualized using FastRed and counterstaining using hematoxylin. No immunoreaction
was observed in sections from SorLA KO (Sorl1/) mice. Eighteen-week-old mice were used.
(C) Confocal image of GFRa1 (green) and SorLA (red) in primary hippocampal neurons fromWTmice (11 DIV). Nuclear staining was obtained usingHoechst (blue).
Scale bar, 10 mm.
(D and E) Surface GFRa1 staining of nonpermeabilized hippocampal neurons (11 DIV) fromWT and SorLA KOmice.White boxes indicate areas of soma and initial
filaments where surface fluorescence was quantified from nonsaturated images using an optical slice of 7 mm of 94 WT and 109 KO neurons on six coverslips of
each genotype from three independent cultures. *p = 3E-6, **p = 7E-6.
(F) Western blot showing GFRa1 in hippocampal neuron lysates derived from WT and SorLA KO (11DIV). Control is lysate of HEK293 cells stably expressing
GFRa1.
(G and H) GDNF (3 nM) was allowed to bind to the surface of hippocampal neurons (11 DIV) of WT and Sorl1/ mice for 2 hr on ice. Cells were subsequently
washed to remove unbound GDNF and incubated for 30min at 37C to allow internalization. Scale bar, 10 mm. n = 3 independent experiments with over 200 cells
evaluated.
See also Figure S6.
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Figure 6. SorLA Reduces In Vivo GDNF
Levels and the Survival of DA Neurons in
Culture
(A) Confocal images of cultured midbrain TH-
positive neurons (red) derived from P0 rats and
grown on a layer of supporting cortical glial cells
for 7 DIV. SorLA (green) is expressed in both glia
and neurons. Scale bar, 10 mm.
(B–D) Primary cultures of mouse cortical glial cells
stained with GFAP (red) display faint immuno-
reaction for endogenousGDNF (green) andGFRa1
(green, Figure S6C) but strong staining for SorLA
(green). Nuclei were stained using Hoechst (blue).
Cells from the Sorl1/ mice are included as
control for the specificity of the SorLA antibody.
(E and F) GDNF (green, 5 nM, 15 min incubation)
is internalized by cortical glial cells from WT but
not from Sorl1/ mice as exemplified using
GFAP-positive glia (red). These cells express some
GFRa1 (Figure S6C). Representative examples
of GDNF-containing vesicular structures are indi-
cated by white arrow heads. n = 3 independent
experiments with over 200 cells evaluated.
(G) Localization of GFRa1(red) in midbrain DA
neurons (4 DIV) identified by TH staining (red). In
the right images, white arrows indicate GFRa1
localized in vesicular structures in soma of a WT
neuron, and surface localized GFRa1 in a KO
neuron.
(H) Survival of primary rat DA neurons (7 DIV)
requires GDNF (0.3 nM) and is enhanced by anti-
SorLA but not by control IgG (10 mg/ml) (p = 0.02,
n = 7).
(I) GDNF-induced survival of WT and KO DA
neurons (4 DIV). TH+ neurons were counted on 14
coverslips of each genotype in three independent
cultures. The survival of SorLA KO DA neurons
stimulated with GDNF was 346% ± 28% of
the unstimulated control, while GDNF-induced
survival in WT neurons was only 194% ± 15% of
the control (*p = 4E-4).
(J) IF on midbrain cryosections showing the pres-
ence of SorLA (green) in TH-positive neurons (red)
of substantia nigra and surrounding glial cells in
16-week-old WT mice but not in SorLA knockouts
of the same age.
(K) GDNF levels determined by ELISA in tissue
homogenates from WT and Sorl1/ mice. GDNF
is increased in midbrain and striatum of KO
animals (p = 0.01, n = 3; each n comprising a pool
of three 12- to 16-week-old animals).
Error bars indicate SEM. See also Figure S6.(p = 0.006) and traveled a distance of approximately 108.62 ±
14.52 m, but no increase was observed following injection of
amphetamine (104.33±6.76m) (Figures7I–7J), strongly suggest-
ing impaired DA functionality in SorLA KOmice. The pronounced
hyperactivity of saline-treated knockouts led us to study their
anxiety-related behavior. In the elevated plus maze, knockouts
displayed markedly reduced anxiety levels evidenced by more
entries and increased time spent in the open arms of the maze
compared to controls (Figures 7K–7M). In striking contrast,
Gdnf+/ mice displayed markedly increased anxiety character-194 Cell Reports 3, 186–199, January 31, 2013 ª2013 The Authorsized by reduced entries and time in the open arms (Figures 7N
and 7O). The combined data show that SorLA is critical for DA
function and anxiety-related behavior. Previous studies have
shown thatSorLAaffectsprocessingof amyloidprecursor protein
(APP) (Andersen et al., 2005) and sorting of lipoprotein lipase
(LpL) to lysosomes (Klinger et al., 2011). However, neither APP
nor LpL has been implicated in DA function so far. It is therefore
tempting to speculate that the impaired DA function in SorLA
KO is mainly caused by altered activity of GDNF and potentially
of other GFLs.
DISCUSSION
We here identify SorLA as a sorting receptor for GDNF and
GFRa1 that traffics a ternary SorLA/GFRa1/GDNF protein
complex from the cell surface to endosomal compartments,
thereby mediating uptake and clearance of extracellular GDNF
as well as redistribution of the GFRa1 receptor pool. The
SorLA/GFRa1 complex further targets RET for endocytosis inde-
pendent of GDNF, thereby altering its subcellular distribution and
signaling. Thus, SorLA represents an example of a transmem-
brane protein that actively mediates trafficking of complexes
of a neurotrophic factor and its receptors. The SorLA/GFRa1
complex is most likely stable once formed, as the affinity is
unusually high for a receptor-receptor interaction (Kd = 6 nM)
considering the restricted diffusion in the cell membrane. For
comparison, this affinity is approximately 5- to 30-fold higher
than what has been reported for Eph-ephrin interactions (Hima-
nen et al., 2004) and at least 70-fold higher than for neurexin-
neuroligin binding in Biacore experiments (Koehnke et al.,
2010). As GFRa1 itself has no cytosolic link to the intracellular
sorting machinery, the docking of the SorLA tail to the adaptors
AP-1 or the retromer complex (Nielsen et al., 2007) also results in
retraction of GFRa1 from late endosomes, subsequent return
to the trans-Golgi and then re-exit to the cell surface for another
round of GDNF capture. The physiological role of SorLA/GFRa1-
mediated trafficking of RET is unclear, but, in exerting its neuro-
trophic function, the RET/GFRa1/GDNF complex is well known
to undergo internalization and retrograde transport from axon
terminals to the soma. This is unlikely to involve SorLA, which
is largely absent from nerve endings (Klinger et al., 2011), and
because the SorLA/GFRa1-mediated RET endocytosis is inde-
pendent of GDNF. However, it is evident, at least in overexpress-
ing cells, that the SorLA/GFRa1-mediated endocytosis of GDNF
and RET is quantitatively more important than internalization of
the RET/GFRa1/GDNF complex.
Through this mechanism, SorLA inhibits downstream effects
of GDNF-induced signaling such as cell survival, proliferation,
and differentiation of neuronal cells, notably the survival of
DA neurons, by lysosomal targeting of GDNF, and by altering
GFRa1/RET subcellular distribution in both neurons and glia.
Future studies will be carried out to dissect how SorLA/GFRa
complexes affect sorting of neurturin, artemin, and persephin,
and what role SorLA might play in other neuronal systems that
depend on GFL activity. Finally, it would be important to address
whether SorLA differentially affects GDNF-induced RET sig-
naling versus RET-independent signaling.
GDNF has received massive attention as a potential treatment
for Parkinson’s disease due to its ability to protect and repair
lesioned nigrostriatal pathway in vivo, but only very little is known
about its role in the intact DA system. In both animal models of
neurotoxicity and human patients, GDNF has been found to
initially potentiate the DA system through increasing TH mRNA
and protein levels, dopamine synthesis, and uptake, and by
enhancing DA target innervation. However, long-lasting overex-
pression of GDNF in rats with lesioned nigrostriatal system led to
downregulation of TH. Similarly, long-term GDNF overexpres-
sion in the striatum of rats with intact nigrostriatal pathway led
to compensatory downregulation of TH with no effect on dopa-Cmine levels (Georgievska et al., 2002, 2004; Rosenblad et al.,
2003) while another study reported reductions in both striatal
TH and dopamine (Sajadi et al., 2005). These observations
have been proposed to reflect compensatory effects of in-
creased GDNF actions on the DA synapse and at the level of
TH expression (Georgievska et al., 2004; Rosenblad et al.,
2003). Contrary, dopamine levels are normal in the striatum
and even increased in the nucleus accumbens of Gdnf+/ mice
compared to their control littermates (Gerlai et al., 2001).
In the present study, we find that SorLA deficiency results in
increased in vivo levels of GDNF that, as may be expected
from the above, translates into reduced striatal TH albeit unal-
tered number of TH+ neurons in the midbrain and normal nigral
fiber length in SorLA KO mice. Increased GDNF activity in the
VTA or nucleus accumbens has been reported to diminish the
behavioral response to drugs of abuse (Carnicella and Ron,
2009). Conversely, infusion of GDNF inhibitory antibodies into
the VTA or lack of one GDNF allele in Gdnf+/ mice increases
the drug response (Messer et al., 2000). Intriguingly, SorLA
knockouts display completely blunted response to amphet-
amine, which is most likely explained by a dramatic reduction
in nigrostriatal connectivity as determined by retrograde tracing.
Such reduced sensitivity to amphetamine is a characteristic of
the dopamine transporter (DAT) knockout (Giros et al., 1996)
andmice lacking a-synuclein (Abeliovich et al., 2000), bothmole-
cules involved in DA synaptic function. Blunted response to
amphetamine has also been reported in mice transgenic for
molecules involved in shaping DA connectivity such as the
netrin-1-receptor-deficient (Grant et al., 2007) or EphA5-overex-
pressing mice (Sieber et al., 2004). The insensitivity toward
amphetamine of SorLA knockouts stands somewhat in contrast
to the previously reported increased response to amphetamine
4 days after a single dose of GDNF or neurturin into the striatum
of mice (Horger et al., 1998). However, the SorLA KO phenotype
may instead reflect an adaptive response to a long-term increase
in GFL activity. SorLA KO mice were further characterized by
marked hyperactivity and reduced anxiety levels, in striking
contrast to mice lacking one GDNF allele, suggesting that the
two could operate together to regulate anxiety-related behavior.
This is interesting, as epigenetic regulation of GDNF expression
was recently proposed to affect susceptibility to stressful events
with its repression correlating with increased anxiety (Uchida
et al., 2011). Thus, SorLA KO animals exhibit behavioral traits
that may model symptoms of psychiatric disorders, in particular,
ADHD, and further studies should validate the potential of
SorLA-deficient mice as an animal model of ADHD. Interestingly,
components of the GDNF system show no genetic associa-
tion with the development of neurodegenerative diseases, but
linkage has been suggested to ADHD, schizophrenia, and other
neuropsychiatric disorders related to dysfunction of the DA
system (Michelato et al., 2004; Souza et al., 2010; Syed et al.,
2007).
We conclude that the interaction among SorLA, GFRa1,
and GDNF is a key regulatory element in the GDNF signaling
through GFRa1-RET. Our results also suggest that SorLA is
a potential target for the treatment of pathological conditions
related to the DA system such as drug abuse and Parkinson’s
disease.ell Reports 3, 186–199, January 31, 2013 ª2013 The Authors 195
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Figure 7. SorLA Affects DA Function and Behavior
(A andB) Number of TH+ neurons is unaltered in the VTA and SNpc ofWT andSorl1/mice as determined by stereological counting (n = 6 of each group, 5-week-
old mice).
(C and D) Normal fiber length density in VTA and SNpc as estimated using global spatial sampling of isotropic virtual planes in thick arbitrarily oriented sections
stained with anti-TH and visualized using DAB (n = 6 of each group, 10-week-old mice).
(E) Retrograde labeling of SNpc TH+ neurons by striatal injection of cholera toxin b subunit (CTb) and subsequently stereological counting of SNpc neurons
positive for both TH and CTb as visualized by double IF. WT (n = 3) and Sorl1/.(n = 4) mice were 10 weeks old. *p = 0.02.
(F and G) Reduced striatal TH levels in SorLA KO mice as assessed by western blotting and quantified relative to b-actin (n = 7, n = 5, respectively, each n
comprising a pool of three 12- to 16-week-old animals). p = 0.01.
(H) Dopamine levels in the striatum of Sorl1/ mice measured using HPLC. p = 0.09, n = 7 and n = 10 for wild-type and knockouts (12–16 weeks old),
respectively.
(I) Representative track plots of WT (n = 12) and Sorl1/ mice (n = 11) during 40 min in the open field following injection of saline or amphetamine
(10 mg/kg).
(J) Quantification of the distance traveled following the injection of saline or amphetamine byWT (n = 6 and n = 6, respectively) and SorLA KOmice (n = 5 and n = 6,
respectively). *p = 2E-4. The activity of saline treated knockouts was also significantly higher than WT (p = 0.006). Mice were 12–16 weeks old.
(K) Representative track plots of WT and Sorl1/ mice during 10 min in the elevated plus maze. Note that while WT mice are most active in the bottom of the
closed arms, knockouts display higher preference toward the open arms.
(legend continued on next page)
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EXPERIMENTAL PROCEDURES
Biacore
Biacore was performed as described (Jacobsen et al., 2001). Binding was ex-
pressed in relative response units (RUs), the difference in response between
the immobilized protein flow cell and the corresponding control flow cell.
Kinetic parameters were determined using BIAevaluation 4.1.
Internalization Assay
Cells were cultured on poly-L-lysine coated coverslips and incubated with
cold medium containing GDNF (3 nM), anti-GFRa1 (0.1 mg/ml), or anti-RET
(0.1 mg/ml) for 2 hr on ice. The culture medium was then changed to 37C
normal medium and at specific time points, and the cells were fixed in 4%
paraformaldehyde (PFA) (pH 7.4) and permeabilized with 0.1% Triton X-100
unless indicated otherwise. Internalized ligand and subcellular markers were
subsequently visualized using IF on a LSM 710 (Carl Zeiss). In different exper-
iments, cells were incubated with GDNF added to 37C medium for defined
time periods. Internalization was quantified from nonsaturated immunofluores-
cent images using ImageJ. Regions of interest were randomly selected along
the plasma membrane of at least 120 cells for each time point. Inhibition of
lysosomal proteinases was achieved by adding fresh medium containing leu-
peptin and pepstatin (50 mg/ml, Sigma-Aldrich) every 6 hr, starting 24 hr before
the experiments.
Metabolic Labeling
Transfected HEK293 or SY5Y cells were labeled using 200 mCi/ml L-[35S]-
cysteine and L-[35S]-methionine (Pro-mix; GE Healthcare) in medium without
methionine and cysteine in the presence of Brefeldin A (Pierce). After 4 hr,
the cells were washed and changed to normal culture medium, and newly
synthesized GFRa1 or RET were chased for specific time periods. GFRa1 or
RET was subsequently immunoprecipitated from cell lysates, separated by
SDS-PAGE, and visualized using phosphoimaging.
DA Cultures
Cultures of DA neuronswere prepared from themidbrain of P0 rats ormice and
grown on a layer of cortical glial cells as described (Burke et al., 1998). Culture
medium was supplemented with 0.3 nM GDNF and changed every 3 days.
The effect of endogenous SorLA in rat DA neurons was assessed by adding
10 mg/ml SorLA antibodies (rabbit anti-human SorLA) or control antibodies
to themedium (rabbit IgG, R&D Systems). The number of surviving DA neurons
was counted at 7 DIV (for rats) or at 4 DIV (for mice) after TH staining.
Behavior
Behavioral tests were performed during the light phase (9 a.m. to 4 p.m.) Mice
were tested for anxiety levels in an elevated plusmaze essentially as described
(Chen et al., 2006). In the open-field test, wild-type and Sorl1/ mice were
administered amphetamine (10 mg/kg) or saline by intraperitoneal (i.p.) injec-
tion, and placed in the corner of a (40 3 40 3 35 cm) clear Plexiglas arena
and their activity was recorded over a 40 min session and analyzed using
the Any-maze tracking software.
Animals
The SorLA KO mouse was first described in Andersen et al. (2005) and has
been backcrossed for ten generations into C57/BL6J. Behavioral studies
were done with the backcrossed homozygous mice compared to the same
C57/BL6J substrain that was used for backcrossing. The behavioral studies
have subsequently been recapitulated using KO andWToffspring from hetero-
zygous breedings. Gdnf+/+ and Gdnf+/ littermates (Pichel et al., 1996) were
obtained by heterozygous breeding using a GDNF KO line that has been back-
crossed for five generations into C57/BL6J. Male mice were used for all exper-(L and M) Sorl1/ mice (n = 12) show more entries (p = 0.01) and spend increase
control mice (n = 9). Mice were 12–16 weeks old.
(N and O) Gdnf+/ mice (n = 4) show fewer entries (p = 0.05) and reduced time
littermates (n = 7). Mice were 11 weeks old.
Error bars indicate SEM. See also Figure S7.
Ciments shown, but similar results were obtained using both genders (data not
shown). Animal experiments were performed according to institutional and
national regulations.
For further details, please see the Extended Experimental Procedures.
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